# Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma

> **NCT01397591** · PHASE2 · TERMINATED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 3 (actual)

## Conditions studied

- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma

## Interventions

- **BIOLOGICAL:** Ofatumumab
- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT01397591
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10
- **Primary completion:** 2013-05
- **Final completion:** 2013-07
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Study closed by PI due to lower than expected accrual.
- **Last updated:** 2014-07-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01397591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01397591, "Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01397591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*